Photo Credit: bit245

The following is a summary of “Effect of vitamin D adjuvant therapy on the proportion of regulatory T cells in peripheral blood and pregnancy outcome of patients with recurrent miscarriage,” November 2024 issue of Obstetrics and Gynecology by Ling et al.     

Recurrent miscarriage (RM), often influenced by immune dysregulation, including abnormalities in regulatory T cells, can increase the risk of pregnancy loss. Vitamin D (VD) has immunoregulatory properties that may positively impact pregnancy outcomes for individuals with RM.  

Researchers conducted a prospective study to assess the effects of VD adjuvant therapy on T cells and pregnancy outcomes in patients experiencing RM.  

They randomly assigned 104 patients with RM (March 2022 to February 2023) to either a VD therapy group (VD group (VDG), 52 patients) or a control group (CG, 52 patients). Both groups received standard treatments (CG: aspirin; VDG: additional VD). T cells, metabolic factors, immune-inflammatory markers, and pregnancy outcomes were evaluated using statistical significance (P<0.05).  

The results showed that after treatment, the VDG had significantly higher T cells proportions (P<0.05). Triglycerides, leptin, fasting blood glucose (FBG), and fasting insulin (FINS) levels were lower, while adiponectin levels were higher in the VDG (P<0.05). Progesterone, luteinizing hormone (LH), and 25-hydroxy VD levels increased in the VDG (P<0.05). Inflammatory markers interleukin-17 (IL-17), gamma interferon (IFN-γ), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) were lower in the VDG (P<0.05). Pregnancy success rates were higher, and preterm birth rates were lower in the VDG (P<0.05).  

They concluded that VD adjuvant therapy enhanced T cells improved immune and metabolic function, and positively influenced pregnancy outcomes in patients with RM.  

Source: obgyn.onlinelibrary.wiley.com/doi/full/10.1111/jog.16151